Table 1.
Activities of compounds in NaCl-resistance assay
| Compound | Conc., mM | Compound/HIV Gag |
|---|---|---|
| Phosphoglycerates | ||
| 2-Phosphoglycerate | >2 | >100 |
| 2,3-Diphosphoglycerate | 1 | 50 |
| Polyphosphates | ||
| Tripolyphosphate | >1 | >50 |
| Tetrapolyphosphate | 0.1 | 5 |
| Sodium phosphate glass* | 0.035 | 2 |
| Inositol phosphates | ||
| IP3 | 0.54 | 27 |
| IP4 | 0.08 | 4 |
| IP5 | 0.002 | 0.1 |
| IP6 | 0.002 | 0.1 |
| Inositol sulfates | ||
| IS6 | >1 | >50 |
| Phosphatidylinositol phosphates | ||
| Dibutyryl PIP3 | 0.057 | 3 |
A number of compounds with multiple phosphate groups are active in inducing formation of NaCl-resistant VLPs. VLPs were assembled in the presence of the indicated compounds (Sigma or Calbiochem), and activity was quantitated using the salt-resistance asay. The minimum concentration of the compound required to produce 100% resistance and the molar ratio of each compound to Gag at that concentration are shown. Where multiple species with the same number of phosphates are listed (e.g., IP3), all the species gave similar results. IP3, D-myo-inositol 1,3,5-triphosphate and D-myo-inositol 3,4,5-triphosphate. IP4, D-myo-inositol 1,3,4,5-tetrakisphosphate, D-myo-inositol 2,3,4,6-tetrakisphosphate, and D-myo-inositol 3,4,5,6-tetrakisphosphate. IP5, D-myo-inositol 1,3,4,5,6-pentakisphosphate. IP6, D-myo-inositol hexakisphosphate. IS6, inositol hexasulfate. Dibutyryl PIP3, a derivative of PIP3 (phosphatidylinositol 3,4,5-trisphosphate) with a truncated (four-carbon) diacylglycerol tail.
Average chain length, 18.